Genpharmasec Limited has announced significant corporate actions following its Board of Directors meeting on November 3, 2026. The company has approved the disinvestment of its entire equity stake in its wholly-owned subsidiary, Clinigenome India Private Limited. Additionally, the resignation of Mr. Hardik Makwana from his positions as Company Secretary and Compliance Officer, effective November 16, 2026, has been accepted. The company also approved its un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
Genpharmasec Board Approves Key Decisions
On November 3, 2026, the Board of Directors of Genpharmasec Limited convened a meeting where several pivotal decisions were made. These decisions included the approval of the company’s un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report from the Statutory Auditor.
Divestment of Subsidiary Announced
A significant resolution passed by the Board was the approval for the disinvestment or sale of the company’s entire equity stake in its wholly-owned subsidiary, Clinigenome India Private Limited. The company clarified that Clinigenome India Private Limited is not a material subsidiary. Upon the completion of this sale, Clinigenome India Private Limited will no longer be a wholly-owned subsidiary of Genpharmasec. Details regarding this transaction are provided in Annexure-A.
Company Secretary Resignation Accepted
In another key development, the Board accepted the resignation of Mr. Hardik Makwana from his roles as Company Secretary and Compliance Officer. His resignation will be effective from the close of business hours on November 16, 2026. The reason cited for his departure is to pursue other professional opportunities. Details concerning this resignation are outlined in Annexure-B.
Financial Highlights for Q2 FY27
The financial results for the second quarter and half-year ended September 30, 2026, were also considered. For the half-year ended September 30, 2026, the standalone Profit Before Tax stood at ₹414.31 Lakhs, contributing to a Total Comprehensive Income of ₹396.81 Lakhs. The standalone revenue from operations for the quarter was ₹5,083.08 Lakhs, and for the half-year, it was ₹9,561.52 Lakhs.
On a consolidated basis for the half-year ended September 30, 2026, the Profit Before Tax was ₹183.70 Lakhs, with a Total Comprehensive Income of ₹68.05 Lakhs. Consolidated revenue from operations for the quarter reached ₹8,565.82 Lakhs and ₹13,536.85 Lakhs for the half-year.
Source: BSE
